NextFin news, The Trump administration announced on Thursday, October 2, 2025, that it will delay the implementation of a 100% tariff on pharmaceutical imports originally scheduled to begin on October 1. This postponement aims to provide additional time to negotiate further drug pricing deals with pharmaceutical companies, following a landmark agreement with Pfizer earlier this week.
President Donald Trump and Pfizer CEO Albert Bourla unveiled the first of several anticipated agreements at the White House, which includes Pfizer offering some of its drugs to Medicaid at prices aligned with those charged internationally. The deal also commits Pfizer to contribute medicines to the upcoming TrumpRx Direct-To-Consumer sales channel, set to launch next year, and guarantees Most-Favoured Nation (MFN) pricing on all new innovative medicines Pfizer introduces in the U.S.
As part of the agreement, Pfizer pledged to invest $70 billion in research and development and manufacturing capacity within the United States. Additionally, Pfizer negotiated a three-year grace period exempting it from the proposed tariffs, a move welcomed by major pharmaceutical groups who have announced significant U.S. capital investments.
Commerce Secretary Howard Lutnick indicated that the administration intends to complete negotiations with other drugmakers before imposing the pharma-specific tariffs. President Trump suggested that companies refusing to enter similar agreements could face even higher tariff rates.
The MFN policy, which the administration is pushing through the threat of tariffs, aims to set U.S. drug prices at the lowest level charged in an OECD country with a GDP per capita at least 60% of that of the U.S. Trump claimed the Pfizer deal would save American consumers "hundreds of millions of dollars a year," although some health policy experts have questioned the impact on patients who do not pay large out-of-pocket drug costs.
Pfizer has not yet revised its financial forecasts following the deal, with close attention expected on its third-quarter results scheduled for November 4, 2025.
This delay and negotiation strategy reflects the administration's approach to leverage tariff threats to achieve lower drug prices while encouraging domestic pharmaceutical investment and manufacturing.
Explore more exclusive insights at nextfin.ai.
